Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918305 | 1.00 | ALK (0.42) | ALKSIGMAR1LTA4HNUAK1TSHR | |
| SCHEMBL23634828 | 1.00 | ALK (0.42) | ALKSIGMAR1LTA4HNUAK1TSHR | |
| SCHEMBL23634903 | 0.91 | SIGMAR1 (0.48) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23634899 | 0.91 | SIGMAR1 (0.48) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23635043 | 0.91 | SIGMAR1 (0.48) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23918302 | 0.89 | HRH3 (0.46) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23635017 | 0.89 | HRH3 (0.46) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23635018 | 0.89 | HRH3 (0.46) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23635014 | 0.88 | SIGMAR1 (0.39) | SIGMAR1NUAK1TSHRHRH3MAOB | |
| SCHEMBL23634904 | 0.88 | SIGMAR1 (0.48) | SIGMAR1HRH3DRD2MAOBCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317109-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | CRBN, CLNS1A, ADRM1 | ALK 1218/4885SIGMAR1 3610/4885LTA4H 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.